Stay updated with breaking news from Jay Bradner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The monoclonal antibody Uplizna met key endpoints in a phase 3 trial for the treatment of IgG4-related disease, marking the first time a placebo-controlled study has shown benefit in the condition, according to a press release from Amgen.Topline results from the double-blind, randomized trial, called MITIGATE, demonstrated an 87% reduced risk for IgG4-related disease (IgG4-RD) flare in patients
USA News Group News Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual meeting approaches, excitement builds over the latest in cancer treatment advancements, particularly in Antibody-Drug Conjugates (ADCs). From May 31 ...
Approximately one in five people worldwide have elevated Lp levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics...
Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics Tina-quant®
Swiss drug major Roche Holding AG (RHHBY) announced Wedensday that the Tina-quant lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.